or Try an Advanced Search...

    Technical Analysis for ELEV - Elevation Oncology, Inc.

    Grade Last Price % Change Price Change
    F 0.54 -6.67% -0.04
    ELEV closed down 6.67 percent on Friday, November 1, 2024, on 1.38 times normal volume.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical ELEV trend table...
    Date Alert Name Type % Chg
    Fell Below 20 DMA Bearish 0.00%
    New Downtrend Bearish 0.00%
    50 DMA Resistance Bearish -6.67%
    Calm After Storm Range Contraction -6.67%
    50 DMA Resistance Bearish -10.67%
    Calm After Storm Range Contraction -10.67%
    50 DMA Resistance Bearish -9.61%
    Gapped Up Strength -9.61%
    1,2,3 Pullback Bullish Bullish Swing Setup -10.02%
    Calm After Storm Range Contraction -10.02%
    Older End-of-Day Signals for ELEV ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 20 hours ago
    Down 5% about 20 hours ago
    20 DMA Support about 22 hours ago
    60 Minute Opening Range Breakdown about 23 hours ago
    1.5x Volume Pace about 23 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ELEV Chart by TradingView
    Basic chart:

    Profile

    Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically-defined patient populations in the United States. Its lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. The company was incorporated in 2019 and is based in New York, New York.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Cancer Clinical Medicine Life Sciences Immunology Health Sciences Pharmacy Treatment Of Cancer Monoclonal Antibody Advanced Solid Tumors Duligotuzumab

    Is ELEV a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 10 What Makes Elevation Oncology (ELEV) a New Strong Buy Stock
    Oct 9 Empery Asset Management's Strategic Acquisition in Elevation Oncology
    Sep 23 Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2
    Sep 3 Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    Aug 7 Elevation Oncology reports data from Phase I trial of EO-3021 for solid tumours
    Aug 6 Elevation Oncology: Proving That No One Knows How To Interpret Early-Stage Clinical Results
    Aug 6 Elevation Oncology GAAP EPS of -$0.18
    Aug 6 Elevation Oncology falls after early-stage data for lead cancer drug
    Aug 6 Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements
    Aug 6 Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2
    See more ELEV news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.8299
    52 Week Low 0.363
    Average Volume 691,874
    200-Day Moving Average 2.61
    50-Day Moving Average 0.61
    20-Day Moving Average 0.56
    10-Day Moving Average 0.59
    Average True Range 0.05
    RSI (14) 39.76
    ADX 30.29
    +DI 17.94
    -DI 20.58
    Chandelier Exit (Long, 3 ATRs) 0.54
    Chandelier Exit (Short, 3 ATRs) 0.65
    Upper Bollinger Bands 0.64
    Lower Bollinger Band 0.48
    Percent B (%b) 0.34
    BandWidth 29.15
    MACD Line -0.02
    MACD Signal Line -0.03
    MACD Histogram 0.0094
    Fundamentals Value
    Market Cap 22.73 Million
    Num Shares 42.4 Million
    EPS -2.03
    Price-to-Earnings (P/E) Ratio -0.26
    Price-to-Sales 0.00
    Price-to-Book 1.97
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.61
    Resistance 3 (R3) 0.61 0.60 0.59
    Resistance 2 (R2) 0.60 0.58 0.59 0.59
    Resistance 1 (R1) 0.57 0.57 0.56 0.56 0.59
    Pivot Point 0.55 0.55 0.55 0.55 0.55
    Support 1 (S1) 0.52 0.53 0.51 0.51 0.49
    Support 2 (S2) 0.50 0.52 0.50 0.48
    Support 3 (S3) 0.47 0.50 0.48
    Support 4 (S4) 0.47